PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
Registrant: E3 STRATEGIC CONSULTING GROUP · 2026 3rd Quarter (July 1 - Sep 30)
$60,000
Reported firm income from this client, all topics
Pharmacy
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.
Lobbyists named: PATRICK FOLEY
Congress inferred from reporting year; verify the bill reference in the source.